What is the official ID of this bill?

The official print number for this legislation is HR 2891.

When did the legislative process begin?

The process officially started on 2021-04-28.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/117/bills/hr2891/BILLS-117hr2891ih.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

Who is the primary sponsor?

The primary sponsor is Rep. Nadler, Jerrold [D-NY-10].

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What is the latest detailed status?

The latest detailed status is: Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 28 - 13.

Analysis and Potential Impact of HR 2891

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

This act aims to lower drug prices by prohibiting delays in market entry of cheaper alternatives.

Q: What are the main provisions?

Key points include: Prohibits payments to delay the market entry of cheaper generic and biosimilar drugs. Introduces financial penalties for companies violating this prohibition, discouraging unfair practices. Aims to increase competition in the pharmaceutical market, which should lead to lower drug prices for consumers.

This act aims to increase the availability of more affordable generic and biosimilar drugs. It prohibits pharmaceutical companies from paying other companies to delay the market entry of cheaper alternatives. As a result, citizens can expect lower drug prices and greater choice, positively impacting their personal finances and access to healthcare.

Key points

Prohibits payments to delay the market entry of cheaper generic and biosimilar drugs.

Introduces financial penalties for companies violating this prohibition, discouraging unfair practices.

Aims to increase competition in the pharmaceutical market, which should lead to lower drug prices for consumers.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

Preserve Access to Affordable Generics and Biosimilars Act

Print number: HR 2891

Sponsor: Rep. Nadler, Jerrold [D-NY-10]

Process start date: 2021-04-28

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash-preview-05-20

Source data: api.congress.gov

AI work logs for this document launch

This act aims to lower drug prices by prohibiting delays in market entry of cheaper alternatives.

Key Questions about This act aims to lower drug prices by prohibiting delays in market entry of cheaper alternatives.